Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27170161
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27170161
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Expert+Opin+Investig+Drugs
2016 ; 25
(8
): 937-56
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Investigational new drugs for brain cancer
#MMPMID27170161
Staedtke V
; Bai RY
; Laterra J
Expert Opin Investig Drugs
2016[Aug]; 25
(8
): 937-56
PMID27170161
show ga
INTRODUCTION: Despite substantial improvements in standards of care, the most
common aggressive pediatric and adult high-grade gliomas (HGG) carry uniformly
fatal diagnoses due to unique treatment limitations, high recurrence rates and
the absence of effective treatments following recurrence. Recent advancements in
our understanding of the pathophysiology, genetics and epigenetics as well as
mechanisms of immune surveillance during gliomagenesis have created new knowledge
to design more effective and target-directed therapies to improve patient
outcomes. AREAS COVERED: In this review, the authors discuss the critical
genetic, epigenetic and immunologic aberrations found in gliomas that appear
rational and promising for therapeutic developments in the presence and future.
The current state of the latest therapeutic developments including tumor-specific
targeted drug therapies, metabolic targeting, epigenetic modulation and
immunotherapy are summarized and suggestions for future directions are offered.
Furthermore, they highlight contemporary issues related to the clinical
development, such as challenges in clinical trials and toxicities. EXPERT
OPINION: The commitment to understanding the process of gliomagenesis has created
a catalogue of aberrations that depict multiple mechanisms underlying this
disease, many of which are suitable to therapeutic inhibition and are currently
tested in clinical trials. Thus, future treatment endeavors will employ multiple
treatment modalities that target disparate tumor characteristics personalized to
the patient's individual tumor.
|Adult
[MESH]
|Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use
[MESH]
free
free
free
